US FDA Extends Age of Use for Dexcom’s Stelo Diabetes Device to 2 Years

The U.S. Food and Drug Administration (FDA) expanded the age indication for Dexcom’s Stelo over-the-counter (OTC) continuous glucose monitor (CGM) to include children as young as 2 years old, according to regulatory updates reported on June 13, 2026. This clearance allows a significantly younger pediatric population to use the non-prescription device for glucose monitoring without requiring a physician’s prescription.

The Stelo system uses a sensor inserted under the skin to track glucose levels in real time, sending data to a compatible smartphone. Previously, the device’s age parameters were more restrictive. The expansion to age 2 marks a shift in how OTC glucose monitoring is accessed for children who do not fit the traditional prescription profiles for insulin-dependent diabetes management.

How does the Stelo CGM differ from prescription monitors?

Stelo is designed specifically as an over-the-counter device, meaning it does not require a healthcare provider’s prescription for purchase. According to Dexcom, the device targets individuals with type 2 diabetes who do not use insulin, as well as health-conscious users who want to track their glucose responses to food and exercise.

This differs from Dexcom’s prescription-only models, such as the G6 and G7. Those devices are indicated for people with type 1 or type 2 diabetes who require insulin and often include advanced features like real-time alerts for hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) that integrate with insulin pumps. Stelo focuses on glucose trends and patterns rather than the acute, minute-by-minute alerts necessary for those managing insulin-induced hypoglycemia.

The primary technical difference lies in the intended use case. While prescription CGMs are medical tools for life-sustaining medication management, Stelo is positioned as a tool for lifestyle modification and general glucose awareness.

Why was the age limit lowered to 2 years?

The decision to lower the age limit follows a documented rise in pediatric type 2 diabetes and a growing demand for non-invasive monitoring in early childhood. According to data from the Centers for Disease Control and Prevention (CDC), the incidence of type 2 diabetes in children and adolescents has increased over the last two decades, often linked to rising childhood obesity rates.

By allowing children as young as 2 to use Stelo, caregivers can monitor glucose fluctuations in toddlers who may be at risk for metabolic issues or those with specific dietary requirements. This removes the barrier of needing a formal prescription for a device that provides more comprehensive data than traditional finger-stick blood glucose meters.

Medical professionals note that the ability to see glucose trends in very young children helps parents identify how specific foods or activities impact a child’s blood sugar without the trauma of frequent needle pricks.

What are the implications for pediatric glucose monitoring?

The shift to OTC access for toddlers changes the diagnostic and management landscape. Historically, pediatric CGM use was reserved for children with type 1 diabetes under strict clinical supervision. With Stelo’s expanded age range, glucose monitoring becomes a consumer-led health activity.

This development creates a contrast in how pediatric glucose data is collected. In a prescription setting, data is typically shared with an endocrinologist via a cloud portal for clinical decision-making. With an OTC device, the data is primarily for the user or guardian, though it can still be shared with providers.

The expansion also raises questions regarding insurance coverage. Most insurance providers cover prescription CGMs for insulin-dependent patients. Because Stelo is OTC, it is generally paid for out-of-pocket, which may create a disparity in access based on socioeconomic status despite the removal of the prescription requirement.

What should caregivers consider when using OTC CGMs?

The FDA’s clearance of the device for children does not replace the need for medical consultation. Dexcom specifies that Stelo is not intended for people with type 1 diabetes or those who use insulin.

Caregivers using the device for children aged 2 and older must be aware of the following:

• Non-Insulin Use: The device is not designed to manage insulin dosing.
• Sensor Placement: Proper application on a toddler’s smaller body surface area is required to ensure accuracy.
• Data Interpretation: Glucose trends in children can vary significantly from adults, requiring a nuanced understanding of “normal” ranges for that specific age group.

The FDA’s move reflects a broader trend toward “democratizing” medical data, shifting the control of health monitoring from the clinic to the home. As more OTC devices enter the market, the distinction between a medical device and a wellness tool continues to blur.